Crystalys Therapeutics

Crystalys Therapeutics Secures $130 Million Series B to Advance Dotinurad for Global Gout Market Entry

Crystalys Therapeutics secured $130 million in Series B financing to accelerate late-stage development and launch preparations for dotinurad, a URAT1 inhibitor for gout. This capital infusion positions Crystalys to challenge existing therapies and creates significant opportunities for CDMOs and supply chain partners preparing for a new entrant in the global gout market.